Astrazeneca annual operating margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Operating Margin Growth & History (AZN)
Astrazeneca's operating margin was 23.40% for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 23.40% | +4.90 pp |
| 2024 | 2024-12-31 | 18.50% | +0.61 pp |
| 2023 | 2023-12-31 | 17.88% | +9.41 pp |
| 2022 | 2022-12-31 | 8.47% | +5.65 pp |
| 2021 | 2021-12-31 | 2.82% | −16.57 pp |
| 2020 | 2020-12-31 | 19.39% | +7.40 pp |
| 2019 | 2019-12-31 | 11.99% | −3.34 pp |
| 2018 | 2018-12-31 | 15.33% | −1.03 pp |
| 2017 | 2017-12-31 | 16.37% | −4.94 pp |
| 2016 | 2016-12-31 | 21.31% | +4.66 pp |
| 2015 | 2015-12-31 | 16.65% | — |
Astrazeneca quarterly operating margin
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 20.57% | −3.70 pp |
| Q1 2026 | 2026-03-31 | 27.77% | — |
| Q4 2025 | 2025-12-31 | 19.21% | — |
| Q3 2025 | 2025-09-30 | 23.59% | — |
| Q2 2025 | 2025-06-30 | 24.27% | +3.04 pp |
| Q2 2024 | 2024-06-30 | 21.22% | −0.29 pp |
| Q2 2023 | 2023-06-30 | 21.51% | +16.51 pp |
| Q2 2022 | 2022-06-30 | 5.00% | −8.71 pp |
| Q2 2021 | 2021-06-30 | 13.71% | −6.75 pp |
| Q2 2020 | 2020-06-30 | 20.46% | +12.00 pp |
| Q2 2019 | 2019-06-30 | 8.47% | −6.33 pp |
| Q2 2018 | 2018-06-30 | 14.80% | −3.51 pp |
| Q2 2017 | 2017-06-30 | 18.31% | — |
Astrazeneca operating margin trends
Over the last five fiscal years, Astrazeneca's operating margin increased from 19.39% to 23.40%, a change of +4.00 percentage points. The latest reported quarter, Q2 2026, shows 20.57%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives priority review for perioperative bladder-cancer regimen
The FDA granted priority review to a regimen combining AstraZeneca ($AZN)’s Imfinzi with enfortumab vedotin around surgery for muscle-invasive bladder cancer in patients ineligible for, or declining, cisplatin chemotherapy. Imfinzi is given ...
AstraZeneca’s Klygefa receives a positive EU recommendation
European medicines advisers recommended AstraZeneca ($AZN)’s Klygefa, or gefurulimab, as an add-on to standard treatment for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The Alexion ...
Enhertu receives European recommendation for an earlier breast-cancer setting
European advisers recommended Enhertu for postoperative treatment of adults with HER2-positive breast cancer who still have invasive disease after preoperative taxane-based chemotherapy and HER2-directed treatment. The drug is jointly devel ...
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...
